[Source: Science Direct, full page: (LINK). Abstract, edited.]
American Journal of Infection Control / Volume 44, Issue 5, Supplement, 2 May 2016, Pages e91–e100 / Disinfection, Sterilization and Antisepsis: Principles, Practices, Current Issues, New Research and New Technologies / Major article
Emerging infectious diseases: Focus on infection control issues for novel coronaviruses (Severe Acute Respiratory Syndrome-CoV and Middle East Respiratory Syndrome-CoV), hemorrhagic fever viruses (Lassa and Ebola), and highly pathogenic avian influenza viruses, A(H5N1) and A(H7N9)
David J. Weber, MD, MPHa, b, William A. Rutala, PhD, MPHa, b, William A. Fischer, MDc, Hajime Kanamori, MD, PhD, MPHa, b, Emily E. Sickbert-Bennett, PhD, MSa, b
a Department of Hospital Epidemiology, University of North Carolina Health Care, Chapel Hill, NC; b Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC; c Division of Pulmonary and Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, NC
Available online 28 April 2016 / doi:10.1016/j.ajic.2015.11.018
Over the past several decades, we have witnessed the emergence of many new infectious agents, some of which are major public threats. New and emerging infectious diseases which are both transmissible from patient-to-patient and virulent with a high mortality include novel coronaviruses (SARS-CoV, MERS-CV), hemorrhagic fever viruses (Lassa, Ebola), and highly pathogenic avian influenza A viruses, A(H5N1) and A(H7N9). All healthcare facilities need to have policies and plans in place for early identification of patients with a highly communicable diseases which are highly virulent, ability to immediately isolate such patients, and provide proper management (e.g., training and availability of personal protective equipment) to prevent transmission to healthcare personnel, other patients and visitors to the healthcare facility.
Key Words: Emerging infectious diseases; health care–associated infections; infection control; occupational health; severe acute respiratory disease; Middle East respiratory syndrome; Lassa fever; Ebola viral disease; novel influenza viruses
Funding/support: Supported by the University of North Carolina at Chapel Hill (U54CK000164).
Publication of this article was supported by an educational grant from Clorox Healthcare, Sealed Air, and Tru-D. Content of this article was initiated and written by the authors with no input or financial support to the authors from Clorox Healthcare, Sealed Air, or Tru-D.
Conflicts of Interest: None to report.
Address correspondence to David J. Weber, MD, MPH, 2163 Bioinformatics, CB #7030, Chapel Hill, NC 27599-7030. (D.J. Weber).
© 2015 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.
Keywords: Research; Abstracts; Lassa Fever; Ebola; H7N9; H5N1; Avian Influenza; MERS-CoV; SARS-CoV.